Michigan House Bill HB4546

Michigan 2025-2026 Regular Session

• Introduced: 6/3/25
• Refer: 6/3/25

Caption

Insurance: health insurers; compliance with the prescription drug cost and affordability review act; require. Amends 1956 PA 218 (MCL 500.100 - 500.8302) by adding sec. 3406tt. TIE BAR WITH: HB 4544'25

Impact

The primary impact of HB4546 is the direct regulation of health insurers concerning the pricing and coverage of prescription medications. By enforcing compliance with the Prescription Drug Cost and Affordability Review Act, the bill aims to enhance transparency and accountability among insurers, ensuring that they do not impose excessive costs on patients. This amendment is expected to lead to a more structured approach in managing drug costs and potentially alleviate some financial burdens on individuals seeking necessary medications.

Summary

House Bill 4546 proposes an amendment to the Insurance Code of 1956 in Michigan, specifically adding section 3406tt. This section mandates that any health insurer delivering or renewing a health insurance policy that includes prescription drug coverage must comply with the provisions set forth in section 12 of the Prescription Drug Cost and Affordability Review Act. This addition underscores the state's commitment to ensuring that healthcare costs, particularly concerning prescription medications, are kept in check for policyholders.

Collateral

Furthermore, the enactment of this bill is tied to the passage of additional legislation, namely Senate Bill No. (pending request no. S00487'25) or House Bill No. 4544. This tie-in suggests that the legislative process around health insurance regulations in Michigan is dynamic and interconnected, potentially affecting how swiftly or effectively changes will be implemented as lawmakers continue to navigate related health policies.

Contention

There are potential points of contention related to this bill, particularly from insurance providers who may argue that increased regulations can lead to higher operational costs. Insurance companies might express concerns over how compliance with the affordability review could affect their pricing strategies and their overall ability to offer competitive health plans. Additionally, there might be debate on the effectiveness of such regulations in genuinely lowering drug prices versus the administrative burden they may impose on insurers.